# Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.

> **NCT07549386** · PHASE3 · COMPLETED · sponsor: **Laboratorios Liomont** · enrollment: 123 (actual)

## Conditions studied

- Pain Management
- Osteoarthritis

## Interventions

- **DRUG:** Etoricoxib 90 mg + diacerein 50 mg
- **DRUG:** Meloxicam 15 mg + diacerein 50 mg

## Key facts

- **NCT ID:** NCT07549386
- **Lead sponsor:** Laboratorios Liomont
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-24
- **Primary completion:** 2025-03-27
- **Final completion:** 2025-10-15
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549386, "Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07549386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*